JP2024054410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024054410A5 JP2024054410A5 JP2024028737A JP2024028737A JP2024054410A5 JP 2024054410 A5 JP2024054410 A5 JP 2024054410A5 JP 2024028737 A JP2024028737 A JP 2024028737A JP 2024028737 A JP2024028737 A JP 2024028737A JP 2024054410 A5 JP2024054410 A5 JP 2024054410A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- igf11
- derived
- light chain
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 241001529936 Murinae Species 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020096344 | 2020-06-02 | ||
| JP2020096344 | 2020-06-02 | ||
| JP2022528850A JPWO2021246413A1 (https=) | 2020-06-02 | 2021-06-01 | |
| PCT/JP2021/020890 WO2021246413A1 (ja) | 2020-06-02 | 2021-06-01 | 抗ｉｇｆ－１受容体ヒト化抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528850A Division JPWO2021246413A1 (https=) | 2020-06-02 | 2021-06-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024054410A JP2024054410A (ja) | 2024-04-16 |
| JP2024054410A5 true JP2024054410A5 (https=) | 2024-06-10 |
Family
ID=78831168
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528850A Pending JPWO2021246413A1 (https=) | 2020-06-02 | 2021-06-01 | |
| JP2024028737A Pending JP2024054410A (ja) | 2020-06-02 | 2024-02-28 | 抗ｉｇｆ－１受容体ヒト化抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528850A Pending JPWO2021246413A1 (https=) | 2020-06-02 | 2021-06-01 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250263489A1 (https=) |
| EP (1) | EP4159860A4 (https=) |
| JP (2) | JPWO2021246413A1 (https=) |
| KR (1) | KR20230006006A (https=) |
| CN (1) | CN115605594A (https=) |
| AR (1) | AR122499A1 (https=) |
| AU (1) | AU2021282629A1 (https=) |
| BR (1) | BR112022022030A2 (https=) |
| CA (1) | CA3176119A1 (https=) |
| CL (1) | CL2022003399A1 (https=) |
| CO (1) | CO2022017026A2 (https=) |
| IL (1) | IL296519A (https=) |
| MX (1) | MX2022015133A (https=) |
| TW (1) | TW202210513A (https=) |
| WO (1) | WO2021246413A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4168046A4 (en) * | 2020-06-18 | 2024-10-16 | Nextcure, Inc. | COMPOSITIONS AND METHODS FOR MODULATING FLRT3-MEDIATED SIGNAL TRANSDUCTION |
| CN114561337B (zh) * | 2022-03-09 | 2023-10-03 | 广州源井生物科技有限公司 | 一种提高HepG2细胞克隆形成率的单克隆增强培养基和方法 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| US20150353643A1 (en) * | 2013-09-24 | 2015-12-10 | Universite De La Mediterranee - Aix-Marseille Ii | Anti-cd277 antibodies and uses thereof |
| ME03560B (me) * | 2012-04-27 | 2020-07-20 | Millennium Pharm Inc | MOLEKULI ANTI-GCC ANTITELA l NJIHOVA UPOTREBA U ISPITIVANJU OSETLJIVOSTI NA GCC-CILJANU TERAPIJU |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| BR112019022789A2 (pt) * | 2017-05-30 | 2020-06-09 | Teijin Pharma Ltd | anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo de produção de um anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, composição farmacêutica, medicamento, método para cultivar células derivadas de vertebrados in vitro, e, animal transgênico. |
| WO2019148410A1 (en) * | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1 antibodies |
| CA3090322A1 (en) * | 2018-02-12 | 2019-08-15 | Diabetes-Free, Inc. | Improved antagonistic anti-human cd40 monoclonal antibodies |
| GB201803892D0 (en) * | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
| TWI850288B (zh) * | 2018-12-03 | 2024-08-01 | 日商帝人製藥股份有限公司 | 抗ｉｇｆ－ｉ受體人源化抗體 |
-
2021
- 2021-06-01 MX MX2022015133A patent/MX2022015133A/es unknown
- 2021-06-01 AR ARP210101492A patent/AR122499A1/es unknown
- 2021-06-01 WO PCT/JP2021/020890 patent/WO2021246413A1/ja not_active Ceased
- 2021-06-01 AU AU2021282629A patent/AU2021282629A1/en active Pending
- 2021-06-01 IL IL296519A patent/IL296519A/en unknown
- 2021-06-01 BR BR112022022030A patent/BR112022022030A2/pt unknown
- 2021-06-01 JP JP2022528850A patent/JPWO2021246413A1/ja active Pending
- 2021-06-01 EP EP21817253.4A patent/EP4159860A4/en active Pending
- 2021-06-01 KR KR1020227042511A patent/KR20230006006A/ko active Pending
- 2021-06-01 CN CN202180039577.1A patent/CN115605594A/zh active Pending
- 2021-06-01 TW TW110119805A patent/TW202210513A/zh unknown
- 2021-06-01 CA CA3176119A patent/CA3176119A1/en active Pending
- 2021-06-01 US US18/007,606 patent/US20250263489A1/en active Pending
-
2022
- 2022-11-28 CO CONC2022/0017026A patent/CO2022017026A2/es unknown
- 2022-12-01 CL CL2022003399A patent/CL2022003399A1/es unknown
-
2024
- 2024-02-28 JP JP2024028737A patent/JP2024054410A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024054410A5 (https=) | ||
| JP2021105034A5 (https=) | ||
| MX2022015133A (es) | Anticuerpo humanizado anti-receptor de igf-1. | |
| CY1124289T1 (el) | Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7 | |
| JP2022031635A5 (https=) | ||
| JP2019122405A5 (https=) | ||
| JP2019054802A5 (https=) | ||
| RU2014142680A (ru) | Способ улучшения функциональных свойств антитела или его антигенсвязывающего фрагмента | |
| JP2016513682A5 (https=) | ||
| BR0318454A (pt) | anticorpos dirigidos a hormÈnio da paratireóide (pth) e seus usos | |
| JP2011173884A5 (https=) | ||
| JP2024156657A5 (https=) | ||
| EP2796466A3 (en) | Humanized antibody molecules specific for IL-31 | |
| PE20061152A1 (es) | Anticuerpos humanizados que reconocen el peptido beta amiloideo | |
| DE602005022928D1 (de) | Antikörper gegen gpnmb und ihre verwendungen | |
| JP2016516400A5 (https=) | ||
| JP2012176953A5 (https=) | ||
| NO20066052L (no) | Anti-CD3 antistoffer og fremgangsmater for anvendelse derav | |
| RU2017102514A (ru) | Гуманизированные анти-тау-антитела | |
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2010536384A5 (https=) | ||
| JP2003528052A5 (https=) | ||
| JP2009225799A5 (https=) | ||
| JP2019506412A5 (https=) | ||
| NO20074867L (no) | Antistoffer mot CCR5 og anvendelser derav |